Overview
TVTX market data
Price History
TVTX price chart · 1M
- O
- 66.34
- H
- 67.81
- L
- 66.34
- C
- 67.68
- Vol
- 28,694.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $66.34
- Previous Close
- $67.14
- Day High
- $67.81
- Day Low
- $66.34
- 52 Week High
- $67.81
- 52 Week Low
- $39.80
- 7 Day Return
- +5.05%
- 30 Day Return
- +21.03%
- 90 Day Return
- +43.42%
- 1 Year Return
- +68.74%
- Daily Notional Volume
- $1.9M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.29 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.11 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -7.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $17.05 – $67.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $5.8B · P/B 29.77 · P/S 9.79.
Company News
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78Benzinga · Aug 10, 2026, 4:38 PM
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70Benzinga · Aug 6, 2026, 11:08 PM
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75Benzinga · Aug 6, 2026, 3:48 PM
TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75Benzinga · Aug 5, 2026, 7:45 PM
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85Benzinga · Aug 5, 2026, 6:31 PM
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68Benzinga · Aug 5, 2026, 3:37 PM
Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On WednesdayBenzinga · Aug 5, 2026, 2:01 PM
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $75Benzinga · Aug 5, 2026, 1:59 PM
Travere Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 5, 2026, 11:42 AM
Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going OnBenzinga · Aug 5, 2026, 7:16 AM